Subcutaneous Testosterone Replacement Efficacy and Safety in Adult Men Diagnosed With Hypogonadism

• Status: Completed
• Trial end date: 0000-00-00
• Target enrollment: 150
• Participant gender: Male

Summary

Evaluation of efficacy and safety of testosterone enanthate administered subcutaneously using an auto-injector

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Antares Pharma Inc.
• Treatments: Methyltestosterone; Testosterone; Testosterone 17 beta-cypionate; Testosterone enanthate; Testosterone undecanoate
• Last Updated: 2015-11-11

Criteria

Inclusion Criteria:

• Adult males aged ≥ 18 year of age with a documented diagnosis of hypogonadism

• Total testosterone levels < 300 ng/dL at two qualification visits

• Patients in good general health

Exclusion Criteria:

• Allergy to sesame or testosterone products

• BMI ≥ 40 kg/m2

• Hematocrit ≥ 52%

• History or current evidence of breast or prostate cancer

• Elevated PSA for age.

• Abnormal DRE

• Obstructive uropathy of prostatic origin

• Poorly controlled diabetes

• Congestive heart failure

• Within 6 months of screening, MI, unstable angina leading to hospitalization, percutaneous coronary intervention, coronary artery bypass graft, uncontrolled cardiac arrhythmia, stroke transient ischemia attack, ceratoid revascularization, endovascular procedure, or surgical intervention for peripheral vascular disease.

• History or current treatment of thromboembolic disease.

• Use of ACTH or oral/depot corticosteroids within 6 weeks of screening.

• History of severe, untreated sleep apnea

• Subjects with any clinically significant medical condition which, in the opinion of the investigator, would make the subject an unsuitable candidate for enrollment in the study

• Positive serology for HIV, hepatitis B or hepatitis C

• Current evidence of drug or alcohol abuse.

• Skin conditions in injection site that could confound injection site assessments.

• Administration of other investigational compounds within one month of screening or 5 half-lives of the investigational compound, whichever is longer).

• Use of estrogen, GnRH or growth hormone within 12 months of screening.

• Use of other androgens (DHEA, anabolic steroids, other sex hormones) or other substances/supplements know to affect the PK of testosterone enanthate

• Considered or scheduled surgical or dental procedures associated with blood loss ≥500 mL during study.

• Donation of plasma or blood within 56 days of screening or history of donation of > 50 mL of blood or plasma within 3 months of screening.

• Donation of plasma or blood during study